(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) In a groundbreaking Phase 2b study, amlitelimab demonstrates remarkable potential in maintaining treatment response for patients with moderate to severe atopic dermatitis (AD). Presented at the American Academy of Dermatology (AAD) 2024 Conference, the study reveals sustained improvement … Read the full press release
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Technology
Tagged #FutureFresenius, CFO, Chief Financial Officer, Deutsche Bank, finance, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Management SE, Fresenius Medical Care, Sara Hennicken, Supervisory Board, transparency, Wolfgang Kirsch
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The event will focus on various aspects, including corporate strategy, sustainability, research and development pipeline, and financial performance. Highlights include discussions … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Capital Markets Day, Novo Nordisk, Strategic Aspirations 2025
(IN BRIEF) Evotec and Claris Ventures have formed a strategic partnership to accelerate the progress of biotech ventures in Claris’s portfolio into clinical trials. This collaboration allows Claris’s portfolio companies, focused on biotech ventures nearing clinical trials, streamlined access to … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Italy, Pharma & Biotech, Science, Technology
(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard care for people with type 2 diabetes and chronic kidney disease (CKD). … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Flow, Kidney, Martin Holst Lange, Novo Nordisk, Ozempic, Semaglutide
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for datopotamab deruxtecan (Dato-DXd), developed by AstraZeneca and Daiichi Sankyo, for the treatment of nonsquamous non-small cell lung cancer (NSCLC) and hormone receptor (HR)-positive, HER2-negative breast … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, EMA, Ken Takeshita, Lung and Breast Cancer Treatment, Marketing Authorisation, Susan Galbraith
(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release
(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Technology
Tagged clinical research project, clinical trial, computerized Tomography, diagnostics, DOTA-TATE Positron Emission Tomography, Dr. Harald Hasselmann, Eckert & Ziegler, Ga-68, GalliaPharm®, Gallium-68, Ge-68, Japan, Japanese Pharmaceuticals and Medical Devices Agency, NCT06240741, NEN, neuroendocrine neoplasms, Novartis Pharma K.K., PET, PMDA, radioisotope supply, rare tumors
(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union (EU) as an add-on to ravulizumab or eculizumab for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience residual haemolytic … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, eculizumab, Marc Dunoyer, PNH, Professor Hubert Schrezenmeier, ravulizumab, safety, treatment, Voydeya
(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
(IN BRIEF) Evonik has partnered with Jland Biotech to introduce vegan collagen for cosmetic and personal care applications. Through an investment from Evonik’s Venture Capital group, the collaboration aims to meet the rising demand for sustainable collagen solutions in skincare. … Read the full press release
Posted in Apparel, Fashion & Beauty, Chemicals, Germany, Pharma & Biotech
Tagged Anti-Aging, collagen, color cosmetics, Cosmetic, Evonik, hair care, hydrating creams, Jland Biotech, Johann-Caspar Gammelin, personal care applications, skin care, skin cleansing, skincare, sun care, Vecollage™ Fortify L, vegan collagen, Vegan Society, Yann d'Hervé
(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024, at 14:00 CET. The meeting will be held partially electronically, allowing shareholders to participate either in person at Bella Center … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Andreas Fibig, appointments, Board Re-election, Christina Law, Helge Lund, Henrik Poulsen, Kasim Kutay, Laurence Debroux, leadership, Martin Mackay, Novo Nordisk, Sylvie Grégoire
(IN BRIEF) Evonik has partnered with the University of Mainz to commercialize a new class of polyethylene glycols (PEGs) called randomized polyethylene glycols (rPEGs). These rPEGs will be integrated into Evonik’s specialized lipid platform for drug delivery in nucleic acid-based … Read the full press release
Posted in Chemicals, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Evonik, immunogenicity, lipid, lipid nanoparticle carriers, lipids, LNP carriers, nucleic acid delivery, nucleic acid-based medicines, PEGs, Polyethylene glycols, polymers, Prof. Dr. Holger Frey, randomized polyethylene glycols, rPEG lipids, rPEG-lipids, rPEGs, specialty chemicals, Thomas Riermeier, University of Mainz
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted by the FDA for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) in patients who have undergone prior … Read the full press release
Posted in Business, Education, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Ken Takeshita, NSCLC Treatment, partnership, Susan Galbraith, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?